Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: Prognostic significance of E2F-1 and p16(INK4A)

Leukemia

Volumn 14, Issue 5, 2000, Pages 898-904

  Moller M B ^b   Kania, P W ^c   Ino, Y ^a   Gerdes, A M ^c   Nielsen, O ^c   Louis, D N ^a   Skjodt K ^c   Pedersen, N T ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NONE

Author keywords

Cyclin D3; E2F 1; Lymphoma; P16; Prognosis; Retinoblastoma gene

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; DNA; PROTEIN P16; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGISTRY; CARCINOGENESIS; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; GENE DELETION; GENE DISRUPTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTRON; LARGE CELL LYMPHOMA; MALE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0034009592     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401761     Document Type: Article

References (61)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
2. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053-1061.
3. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487-497.
4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
5. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
6. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9: 3375-3378.
7. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-153.
8. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, lames CD. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-5807.
9. ARI links the tumour suppressors RB and p53. Nature 1998; 395: 124-125.
10. Arl, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
11. Wingo PA, Ries LAG, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, Thun MJ, Edwards BK. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91: 675-690.
12. 2 Chan WC, Armitage JO, Gascoyne R, Connors J, Close P, Jacobs P, Norton A, Lister TA, Pedrinis E, Cavalli F, Berger F, Coiffier B, Ho F, Liang R, Schauer A, Hiddemann W, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Weisenburger DD, Harris NL, Anderson JR, Roy P. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918.
13. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK. SEER Cancer Statistics Review, 1973-1996. National Cancer Institute: Bethesda, 1999.
14. Offit K, Chaganti RSK. Chromosomal aberrations in non-Hodgkin's lymphoma. Biologic and clinical correlations. Hematol Oncol Clin North Am 1991; 5: 853-869.
15. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RSK, Dalla-Favera R. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747-750.
16. Møller MB, Ino Y, Gerdes A-M, Skjodt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 1999; 13: 453-459.
17. Kip1. Br J Haematol 1999; 105: 730-736.
18. Møller MB, Gerdes A-M, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B-and T-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5: 1085-1091.
19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Piris MA, Raltkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
20. Møller MB, d'Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. Eur J Cancer 1994; 30A: 1760-1764.
21. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister TA, Meerwald JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WA, Yeap BY. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993; 329: 987-994.
22. Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood 1996; 88: 268-276.
23. Doglioni C, Chiarelli C, Macri E. Dei Tos AP, Meggiolaro E, Dalla Palma P, Barbareschi M. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol 1998; 185: 159-166.
24. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11: 457-463.
25. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Over-expression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995; 146: 1161-1169.
26. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE. Altered expression of the retinoblastoma gene produkt: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251-1256.
27. Grierson AJ, Hodgkins MA, Hancock BW, Goepel JR, Royds J, Goyns MH. Investigation of the RB-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas. Leuk Lymphoma 1996; 23: 353-363.
28. Aguilera NSI, Bijwaard KE, Duncan B, Krafft AE, Chu WS, Abbondanzo SL, Lichy JH, Taubenberger JK. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. Am J Pathol 1998; 153: 1969-1976.
29. Yandell DW, Dryja TP. Detection of sequence polymorphisms by enzymatic amplification and direct genomic sequencing. Am J Hum Genet 1989; 45: 547-555.
30. Liu Y, Rasool O, Grandér D, Lindblom A, Einhorn S. Sequence variability of a prolonged tetranucleotide repeat. Hum Mol Genet 1995; 4: 727-729.
31. Peltomäki P, Aaltonen LA, Sistonen P, Pylkkänen L, Mecklin JP, Jävinen H, Green JS, Jass JR, Weber JL, Leach FS, Pedersen GM, Hamilton SR, de la Chapelle A, Vogelstein B. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993; 260: 810-812.
32. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 1993; 67: 1262-1267.
33. Shimizu T, Toguchida J, Kato MV, Kaneko A, Ishizaki K, Sasaki MS. Detection of mutations of the RB1 gene in retinoblastoma patients by using exon-by-exon PCR-SSCP analysis. Am J Hum Genet 1994; 54: 793-800.
34. Hogg A, Onadim Z, Baird PN, Cowell JK. Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand confirmation polymorphism analysis and polymerase chain reaction sequencing. Oncogene 1992; 7: 1445-1451.
35. Lohmann DR, Brandt B, Höpping W, Parsarge E, Horsthemke B. Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma. Hum Genet 1994; 94: 349-354.
36. Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW, Dryja TP. Complete genomic sequence of the human retinoblastoma susceptibility gene. Genomics 1993; 17: 535-543.
37. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989; 7: 1630-1636.
38. Martinez JC, Piris MA, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Martinez P. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. J Pathol 1993; 169: 405-412.
39. Nguyen PL, Zukerberg LR, Benedict WF, Harris NL. Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. Am J Clin Pathol 1996; 105: 538-543.
40. Barrans SL, Haynes A, Fegan C, Jack AS, Morgan GJ. Immunohistochemical analysis of cell proliferation and oncogene expression in nodal diffuse large B-cell lymphoma. Br J Haematol 1997; 97: 31 (Abstr.).
41. Geradts J, Andriko JW, Abbondanzo SL. Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol 1998; 109: 669-674.
42. Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993; 81: 166-176.
43. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992; 90: 41-54.
44. Koeberl DD, Bottema CDK, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS. Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene. Am J Hum Genet 1990; 47: 202-217.
45. Weide R, Tiemann M, Pflüger K-H, Köppler H, Parvizl B, Wacker H-H, Kreipe HH, Havemann K, Parwaresch MR. Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. Leukemia 1994; 8: 97-101.
46. Hayashi K, Yandell DW. How sensitive is PCR-SSCP? Hum Mutat 1993; 2: 338-346.
47. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993; 8: 1063-1067.
48. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998; 17: 1027-1037.
49. Petrucci MT, Ariola C, Ricciardi MR, Pisegna S, Fimia GM, Annino L, Testi AM, Lo Coco F, Mandelli F, Tafuri A. Molecular control of cell cycle in normal and neoplastic hemopoiesis: p16, CDK4, and Rb showed a common tumorigenesis pattern in acute lymphoblastic leukemia. Blood 1996; 88: 120b (Abstr.).
50. Ando K, Griffin JD. Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene 1995; 10: 751-755.
51. Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddemann W, Döhner H. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 1997; 57: 4608-4614.
52. INK4A as upstream regulators of Myc. Oncogene 1997; 15: 179-192.
53. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994; 54: 6078-6082.
54. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci USA 1998; 95: 8858-8863.
55. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
56. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
57. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998; 58: 4292-4296.
58. Volm M, Koomägi R, Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer 1998; 79: 294-299.
59. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Cordon-Cardo C. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999; 91: 874-881.
60. Garcia-Sanz R, Gonzalez M, Vargas M, Chillon MC, Balanzategui A, Barbon M, Flores MT, San Miguel JF. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997; 11: 1915-1920.
61. Grønbøk K, de Nully Brown P, Ralfkiaer E, Zeuthen J, Guldberg P. Concurrent disruption of the p16-pRb and ARF-p53 pathways predicts poor prognosis in non-Hodgkin's lymphoma. Proc Am Assn Cancer Res 1999; 40: 282 (Abstr.).